Guang Yang

Guang Yang

Auto-generated profile, based on publicly available information

Guang Yang

Shanghai Research Institute of Acupuncture and Meridian, Shanghai, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2024 in Clinical and Translational Medicine
Verified
Journal Article
Open access
LWLin Wan
Lin Wan
HWHuan Wang
Huan Wang
YLYan Liang
Yan Liang
XZXun Zhang
Xun Zhang
XYXinyun Yao
Xinyun Yao
GYGuang Yang
Guang Yang

1 January 2021 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
XKXie-He Kong
Xie-He Kong
YZYue Zhao
Yue Zhao
ZCZhi Chen
Zhi Chen
LZLi Zeng
Li Zeng
RHRong Han
Rong Han
XMxiaopeng ma
xiaopeng ma
Background . Use of 0.01% atropine eye drops (0.01% A) is one of the most common treatments for myopia control for children in Asia. Auricular acupoint stimulation (AAS) was reported to enhance the effect of higher‐concentration atropine (0.25%, 0.125%) on myopia control. This study was designed to compare the effect of 0.01% A combined with AAS and 0.01% A alone on myopia progression and choroidal thickness in children. Methods . A total of 104 children were stratified by age and randomly assigned at 1 : 1 to receive 0.01% A or 0.01% A + AAS treatment for 6 months. Repeated measurements of cycloplegic spherical equivalent (SE) autorefraction, axial length (AL), and choroidal thickness were performed at baseline, 1 month, 3 months, and 6 months. Results . The adjusted mean SE change over the 6 months was −0.38 ± 0.04 D in the 0.01% A group ( n = 50) and −0.25 ± 0.04 D in the 0.01% A + AAS group ( n = 50), demonstrating a significant between‐group difference ( P = 0.02). There was no statistically significant difference in the change of AL and choroidal thickness between the two groups (both P > 0.05). Conclusions . Adjunctive AAS compared with 0.01% A monotherapy slowed myopic progression in Chinese children by a statistically small amount, but had no effect on axial elongation and choroidal thickness during this 6‐month observation. The trial is registered with ChiCTR1900021316 .

17 October 2022 in Acta Ophthalmologica
Verified
Journal Article
Closed access
GYGuang Yang
Guang Yang
XKXiehe Kong
Xiehe Kong
XGXiaocong Guo
Xiaocong Guo
YYYanting Yang
Yanting Yang
CXChen Xie
Chen Xie
XMxiaopeng ma
xiaopeng ma

1 April 2009 in Molecular Immunology
Verified
Journal Article
Closed access
DHDali Hu
Dali Hu
XSXuejin Su
Xuejin Su
RSRan Sun
Ran Sun
GYGuang Yang
Guang Yang
HWHuaying Wang
Huaying Wang
LWLiying Wang
Liying Wang

7 June 2021 in Trials
Verified
Journal Article
Open access
PDF file
RHRong Han
Rong Han
XKXie-He Kong
Xie-He Kong
FZFeng Zhao
Feng Zhao
YYYanting Yang
Yanting Yang
XDXiao-Qing Dong
Xiao-Qing Dong
XMxiaopeng ma
xiaopeng ma
Background: Nowadays, because of the increasing incidence, the prevention and control of myopia has become an urgent issue. In China, auricular acupressure has been commonly used in the clinical treatment of myopia in children, but the exact effectiveness remains unproven. The purpose of this trial is to observe the efficacy of auricular acupressure in myopia prevention and control, as well as its effect on the choroidal and retinal thickness. Method/design: A total of 480 subjects at 8–9 years old will be randomized in a 1:1 ratio to an intervention group versus a control group. The intervention group will receive auricular acupressure for 12 months, while the control group will be taken as a blank control. The primary and secondary outcomes will be measured at baseline, and again at 3, 6, 9, and 12 months after recruitment. The myopia incidence (spherical equivalent ≤ − 0.50 D) and the mean change of spherical equivalent will be taken as the primary variables; the secondary outcome measures include axial length, uncorrected visual acuity, and choroidal and retinal thickness. Discussion: This trial aims to evaluate the effectiveness of auricular acupressure for myopia prevention and control with objective evidence and to preliminarily explore the plausible mechanism and provide reference for adopting this approach to retard the onset and control the progression of myopia. Trial registration: Chinese Clinical Trial Registry ChiCTR2000038456. Registered on September 23, 2020.

30 March 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
XKXiehe Kong
Xiehe Kong
RHRong Han
Rong Han
XFXiaopeng Fan
Xiaopeng Fan
KWKai Wei
Kai Wei
ZMZhao Ma
Zhao Ma
XMxiaopeng ma
xiaopeng ma
Background: Preclinical studies suggest acupuncture may offer symptomatic relief or modify disease progression in Alzheimer's disease (AD), yet clinical evidence remains limited. Objective: This study evaluated whether adding acupuncture to cholinesterase inhibitors improves outcomes in patients with mild AD and whether any benefits persist after treatment ends. Methods: In this randomized, single-blind trial, participants with mild AD received either active or sham acupuncture three times per week for 14 weeks in addition to ongoing donepezil therapy, followed by a 14-week washout phase during which acupuncture was discontinued while donepezil was maintained. The primary outcome was change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog12) from baseline. Results: A total of 160 participants were enrolled, and 157 were included in the primary analysis (78 active, 79 sham). At week 14, the mean change in ADAS-cog12 was −1.20 for the active acupuncture group versus 0.36 for the sham acupuncture group, yielding a difference of −1.50 (p < 0.001). After washout, no significant difference remained (difference, −0.31; p = 0.54). Adverse events occurred in 37.2% of the active and 45.6% of the sham group. Donepezil-related adverse events were less frequent with active acupuncture (6.4% versus 16.5%; p < 0.05). Conclusions: Acupuncture, when added to donepezil, improved cognition during active treatment and was associated with fewer cholinergic side effects in patients with mild AD. The cognitive benefits did not persist after acupuncture was discontinued, suggesting that acupuncture serves as an adjunctive symptomatic therapy rather than a disease-modifying intervention. Trial registration: ClinicalTrials.gov [NCT05078944].